References
[1] Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality [J]. Epilepsia, 2008;49(suppl 1):8-12.
[2] Hauser WA. Status Epilepticus: epildemiologic considerations [J]. Neurology, 1990, 40(Supp12): 9-13.
[3] Savage TE, Sourbron J, Bruno PL, et al. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. Epilepsy Res 2019; 160:106263. DOI:10.1016/j.eplepsyres.2019.106263.
[4] Vezzani A, Balosso S, Ｒavizza T. Inflammation and epilepsy [J]. Handb Clin Neurol, 2012, 107: 163-175.
[5] Vezzani A, French J, Bartfai T, et al. The role of inflammation inepilepsy [J]. Nat Ｒev Neurol, 2011, 7: 31-40.
[6] Choi, J. Min, H. J. Shin, J. Increased levels of HMGB1 and pro-inflammatory cytokines in children with febrile seizures 1743-2094. DOI:10.1186/1742-2094-8-135.
[7] Feng, Z. H. Hao, J. W. Ye, L. Dayao, C. Yan, N. Yan, Y. Chu, L. Shi, F. D. Overexpression of mu-calpain in the anterior temporal neocortex of patients with intractable epilepsy correlates with clinicopathological characteristics 1059-1311 DOI:10.1016/j.seizure.2011.01.010.
[8] Dundar, N. O. Aktekin, B. Ekinci, N. C. Sahinturk, D. Yavuzer, U. Yegin, O. Haspolat, S. Interleukin-1beta secretion in hippo-campal sclerosis patients with mesial temporal lobe epilepsy 2035-8385. DOI:10.4081/ni.2013.e17.
[9] Pollard, J. R. Eidelman, O. Mueller, G. P. Dalgard, C. L. Crino, P. B. Anderson, C. T. Brand, E. J. Burakgazi, E. Ivaturi, S. K. Pollard, H. The TARC/sICAM5 ratio in patient plasma is a candidate biomarker for drug-resistant epilepsy 1664-2295. DOI:10.3389/fneur.2012.00181.
[10] Bartolini, L. Piras, E. Sullivan, K. Gillen, S. Bumbut, A. Lin, C. T. Leibovitch, E. C. Graves, J. S. Waubant, E. L. Chamberlain, J. M. Gaillard, W. D. Jacobson, S. Detection of HHV-6 and EBV and Cytokine Levels in Saliva From Children With Seizures: Results of a Multi-Center Cross-Sectional Study. 1664-2295. DOI:10.3389/fneur.2018.00834.
[11] Pedre, L. L. Chacon, L. M. M. Fuentes, N. P. Agramonte, M. D. R. Sanchez, T. S. Cruz-Xenes, R. M. Hung, M. L. D. Diaz, B. E. Martin, M. M. B. Orozco-Suarez, S. Follow-Up of Peripheral IL-1 and IL-6 and Relation with Apoptotic Death in Drug-Resistant Temporal Lobe Epilepsy Patients Submitted to Surgery. 2076-328X. DOI:10.3390/bs8020021.
[12] Farias-Moeller, R. LaFrance-Corey, R. Bartolini, L. Wells, E. M. Baker, M. Doslea, A. Suslovic, W. Greenberg, J. Carpenter, J. L. Howe, C. L. Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome 0013-9580. DOI:10.1111/epi.14524.
[13] Pollandt S. Thermoregulation in epilepsy. Handb Clin Neurol 2018;157:737-747.DOI:10.1016/B978-0-444-64074-1.00045-8.
[14] Terrone G, Frigerio F, Balosso S, et al. Inflammation and reactive oxygen species in status epilepticus: Biomarkers and implications for therapy. Epilepsy Behav 2019; 106275. DOI:10.1016/j.yebeh.2019.04.028.
[15] van Vliet EA, Aronica E, Vezzani A. Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies. Neuropathol Appl Neurobiol 2018; 44:91-111.
DOI:10.1111/nan.12444.
[16] Pressler RM. Why we urgently need improved seizure and epilepsy therapies for children and neonates. Neuropharmacology 2019; 107854. DOI:10.1016/j.neuropharm.2019.107854.